We are live on
!
Find out more
A
AJOVista Portfolio holdings
AUM
$23.4M
1-Year Est. Return
76.18%
This Fund
S&P 500
This Quarter
Est. Return
+29.83%
1 Year Est. Return
+76.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$23.4M
AUM Growth
-$11.3M
(-33%)
Cap. Flow
-$13.9M
Cap. Flow
% of AUM
-59.37%
Top 10 Holdings %
Top 10 Hldgs %
39.09%
Holding
175
New
100
Increased
8
Reduced
3
Closed
63
Top Buys
| 1 |
KE Holdings
BEKE
|
+$1.56M |
| 2 |
Qfin Holdings
QFIN
|
+$1.24M |
| 3 |
JD.com
JD
|
+$852K |
| 4 |
Alibaba
BABA
|
+$723K |
| 5 |
Vale
VALE
|
+$325K |
Top Sells
| 1 |
iShares MSCI Saudi Arabia ETF
KSA
|
+$6.05M |
| 2 |
Apple
AAPL
|
+$2.32M |
| 3 |
NVIDIA
NVDA
|
+$2.3M |
| 4 |
Microsoft
MSFT
|
+$2.19M |
| 5 |
Amazon
AMZN
|
+$1.36M |
Sector Composition
| 1 | Consumer Discretionary | 20.05% |
| 2 | Healthcare | 18.93% |
| 3 | Financials | 12.06% |
| 4 | Materials | 9.82% |
| 5 | Real Estate | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Heron Therapeutics
HRTX
$89.1M
| $44.8K | 0.19% |
22,492
+2,774
| +14% | +$6.62K |
|
102
CytomX Therapeutics
CTMX
$788M
| $39.1K | 0.17% |
+33,121
| New | +$42.1K |
|
103
Trevi Therapeutics
TRVI
$2.71B
| $38.4K | 0.16% |
+11,495
| New | +$34.2K |
|
|
CMRX
104
DELISTED
Chimerix, Inc.
CMRX
| $35.6K | 0.15% |
+38,329
| New | +$34.2K |
|
105
SES AI
SES
$236M
| $31.8K | 0.14% |
+49,708
| New | +$51.9K |
|
106
Gevo
GEVO
$397M
| $31.5K | 0.13% |
+19,342
| New | +$15.7K |
|
107
CuriosityStream
CURI
$152M
| $31.1K | 0.13% |
+16,266
| New | +$22.2K |
|
|
VTYX
108
DELISTED
Ventyx Biosciences
VTYX
| $27.4K | 0.12% |
+12,550
| New | +$28.9K |
|
109
Upland Software
UPLD
$15.8M
| $26.6K | 0.11% |
+1,069
| New | +$24.6K |
|
110
Aclaris Therapeutics
ACRS
$793M
| $20.1K | 0.09% |
+17,455
| New | +$21.4K |
|
111
SCYNEXIS
SCYX
$42.4M
| $16.4K | 0.07% |
+1,374
| New | +$19.4K |
|
|
OPTN
112
DELISTED
OptiNose
OPTN
| $7.58K | 0.03% |
+754
| New | +$11K |
|
113
Agilent Technologies
A
$37.1B
| – | – |
-1,591
| Closed | -$206K |
|
|
114
Apple
AAPL
$4.9T
| – | – |
-10,993
| Closed | -$2.32M |
|
115
AbbVie
ABBV
$450B
| – | – |
-1,611
| Closed | -$276K |
|
116
Adobe
ADBE
$94.3B
| – | – |
-370
| Closed | -$206K |
|
117
ADMA Biologics
ADMA
$2.02B
| – | – |
-10,474
| Closed | -$117K |
|
118
Autodesk
ADSK
$46.1B
| – | – |
-856
| Closed | -$212K |
|
119
Advanced Micro Devices
AMD
$808B
| – | – |
-1,402
| Closed | -$227K |
|
120
Amgen
AMGN
$198B
| – | – |
-659
| Closed | -$206K |
|
|
121
Amazon
AMZN
$2.66T
| – | – |
-7,025
| Closed | -$1.36M |
|
122
Autohome
ATHM
$2.48B
| – | – |
-36,594
| Closed | -$1M |
|
123
Broadcom
AVGO
$1.76T
| – | – |
-2,840
| Closed | -$456K |
|
124
American Express
AXP
$242B
| – | – |
-1,048
| Closed | -$243K |
|
125
Bank of America
BAC
$430B
| – | – |
-7,522
| Closed | -$299K |
|
Similar funds
TM
CMG
SRCM
LC
KLM
OCM
PFG
ICP
AJOVista's Q3 2024 Portfolio in Review
As of Q3 2024, AJOVista held 175 positions worth $23.4M, down 33% from $34.7M the previous quarter. Its ten largest holdings account for 39% of the portfolio.
AJOVista withdrew a net $13.9M in Q3 2024, closing 63 positions and reducing 3 holdings. Its most notable exit was Apple, an estimated $2.32M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 20% of assets, up from 9.4% a quarter earlier, followed by Healthcare and Financials.
Against the trend, AJOVista opened a new position in KE Holdings worth $2.1M.
- AJOVista's largest Q3 2024 buy was KE Holdings: 105,472 shares worth $2.1M.
- AJOVista added most to Eagle Pharmaceuticals, Inc. in Q3 2024, an estimated $216K increase.
- AJOVista's biggest Q3 2024 reduction was iShares MSCI Saudi Arabia ETF, cutting an estimated $6.05M.
- AJOVista fully exited Apple in Q3 2024, selling an estimated $2.32M.
- AJOVista's ten largest holdings make up 39% of its $23.4M portfolio in Q3 2024.
- AJOVista opened 100 new positions and closed 63 in Q3 2024.
- AJOVista's portfolio value fell 33% quarter-over-quarter to $23.4M.
Based on AJOVista's 13F filing for Q3 2024, filed 12 Nov 2024.